A
Andreea Picu
Researcher at University of Turin
Publications - 26
Citations - 801
Andreea Picu is an academic researcher from University of Turin. The author has contributed to research in topics: Cortisol secretion & Adrenocorticotropic hormone. The author has an hindex of 15, co-authored 26 publications receiving 752 citations.
Papers
More filters
Journal ArticleDOI
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
Roberta Giordano,Andreea Picu,Elisa Marinazzo,Valentina D’Angelo,Rita Berardelli,Ioannis Karamouzis,D. Forno,Domenico Zinnà,Mauro Maccario,Ezio Ghigo,Emanuela Arvat +10 more
TL;DR: Cushing’s syndrome is associated with several comorbidities responsible for the increased cardiovascular risk, not only during the active phase but also after disease remission.
Journal ArticleDOI
Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-Secretagogue-receptor modulation.
Roberta Giordano,Micaela Pellegrino,Andreea Picu,Lorenza Bonelli,Marcella Balbo,Rita Berardelli,Fabio Lanfranco,Ezio Ghigo,Emanuela Arvat +8 more
TL;DR: GABA agonists (mainly ALP), ghrelin, as well as MR agonists/antagonists, may represent good tools to explore the activity of the HPA axis in both physiological conditions and pathological states characterized by an impaired control of the corticotroph function.
Journal ArticleDOI
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.
Francesca Pecori Giraldi,Carla Scaroni,Emanuela Arvat,Martina De Martin,Roberta Giordano,Nora Albiger,Adriana A. S. Leao,Andreea Picu,Franco Mantero,Francesco Cavagnini +9 more
TL;DR: This work has shown that peroxisome proliferator‐activated receptor gamma (PPARγ) agonists effectively suppress ACTH secretion in a murine tumoral corticotroph cell line, but the few studies conducted so far in patients with ACTH‐secreting pituitary adenomas have yielded variable results.
Journal ArticleDOI
Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas.
Roberta Giordano,Elisa Marinazzo,Rita Berardelli,Andreea Picu,Mauro Maccario,Ezio Ghigo,Emanuela Arvat +6 more
TL;DR: The risk of mass enlargement, hormonal, and metabolic impairment over time is globally low, and Conservative management seems to be appropriate in adrenal incidentalomas, but further prospective studies are needed to establish the long-term outcome of such patients.
Journal ArticleDOI
Hypothalamus–pituitary–adrenal axis evaluation in patients with hypothalamo–pituitary disorders: comparison of different provocative tests
Roberta Giordano,Andreea Picu,L. Bonelli,M. Balbo,Rita Berardelli,Elisa Marinazzo,G. Corneli,Ezio Ghigo,Emanuela Arvat +8 more
TL;DR: A gold standard test to evaluate hypothalamic–pituitary–adrenal (HPA) axis in suspected ACTH insufficiency and the diagnostic reliability of 1·0 µg ACTH test is controversial and very low doses have been proposed.